플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Qingjin Yiqi granules for post-COVID-19 condition: A randomized clinical trial.

Authors

Pang W, Yang F, Zhao Y, Dai E, Feng J, Huang Y, Guo Y, Zhou S, Huang M, Zheng W, Ma J, Li H, Li Q, Hou L, Zhang S, Wang H, Liu Q, Zhang B, Zhang J.

Journal

J Evid Based Med.

Year

2022

Vol (Issue)

15(1)

Page

30-8.

doi

10.1111/jebm.12465.

PMID

35416437

Url

http://www.ncbi.nlm.nih.gov/pubmed/35416437

MeSH

COVID-19* / drug therapy
Humans
Treatment Outcome

Keywords

COVID-19; Qingjin Yiqi granules; post-COVID-19 condition; randomized clinical trial; rehabilitation treatment

한글 키워드

코로나19; 청금익기과립; 코로나19 후 증상; 무작위배정 비교임상시험; 재활 치료

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

Objective: To evaluate the effectiveness and safety of Qingjin Yiqi granules (QJYQ) on post-COVID-19 condition (PCC).

Method: Patients who met the inclusion criteria were randomly assigned to two groups, the QJYQ group received QJYQ combined with standard rehabilitation treatments (SRTs) and the control group only received SRTs. The treatment course was 14 days. The primary outcomes were modified Medical Research Council (mMRC) scale and Borg scale, while the secondary outcomes included symptoms score and 6-minute walking distance (6MWD). The safety outcome was the incidence of adverse events.

Results: A total of 388 patients with PCC were enrolled and randomly assigned to the QJYQ group (n = 194) and the control group (n = 194). Compared to the controls, the mMRC scale was improved in the QJYQ group, which was better than that of the control group [β (95%CI): -0.626 (-1.101, -0.151), p = 0.010]. A significant improvement in Borg scale was also observed in the QJYQ group compared to the control group [β (95%CI): -0.395(-0.744, -0.046), p = 0.026]. There was no statistically significant difference in symptoms score and 6MWD between the two groups (p = 0.293, p = 0.724). No treatment-related adverse events were observed in either group.

Conclusions: QJYQ can bring benefits to patients with PCC, mainly in the improvement of breathlessness and fatigue.

© 2022 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.

국문초록

N

Language

영어

첨부파일